Assessment of QoL and Outcomes With SBRT for RCC
AQuOS-RCC
Assessment of Quality of Life and Outcomes in Patients Treated With Stereotactic Body Radiation Therapy (SBRT) for Primary Renal Cell Carcinoma (RCC) - AQuOS-RCC
1 other identifier
interventional
30
1 country
2
Brief Summary
Stereotactic body radiotherapy (SBRT) is an emerging radiotherapy technique that precisely delivers high doses of radiation to tumours. It has been investigated as definitive treatment for an increasing variety of primary tumours including lung, liver, prostate, and now renal cell carcinoma (RCC). The principal aims of this study are to prospectively assess quality of life (QoL) and oncologic outcomes in non-surgical patients who receive SBRT for the treatment of RCC.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jun 2015
Longer than P75 for not_applicable
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2015
CompletedFirst Submitted
Initial submission to the registry
March 19, 2017
CompletedFirst Posted
Study publicly available on registry
April 11, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2025
CompletedDecember 7, 2023
December 1, 2023
10.5 years
March 19, 2017
December 5, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Patient Quality of Life
To evaluate quality of life scores
Up to 5 years after treatment
Secondary Outcomes (5)
Cost-Effectiveness
Up to 5 years after completion of treatment
Oncologic Outcomes
Up to 5 years after completion of treatment
Oncologic Outcomes
Up to 5 years after completion of treatment
Oncologic Outcomes
Up to 5 years after completion of treatment
Treatment-Related Toxicity
Up to 5 years after completion of treatment
Study Arms (1)
SBRT
EXPERIMENTALRCC patients
Interventions
Eligibility Criteria
You may qualify if:
- Patients ≥18 years old
- Medically inoperable or patient who refuses surgery
- Histologic diagnosis of RCC where possible, or radiologic evidence of growth on surveillance
- Lesion ≥2.5cm or recurrent lesion following local ablative therapy
- Written informed consent
- Participants must be able to understand the English-language or with the aid of a translator
You may not qualify if:
- ECOG ≥3
- Prior abdominal radiation
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Sunnybrook Health Sciences Centrelead
- Juravinski Cancer Centercollaborator
Study Sites (2)
Juravinski Cancer Centre
Hamilton, Ontario, L8V 5C2, Canada
Odette Cancer Centre, Sunnybrook Health Science Centre
Toronto, Ontario, M4N 3M5, Canada
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Radiation Oncologist
Study Record Dates
First Submitted
March 19, 2017
First Posted
April 11, 2017
Study Start
June 1, 2015
Primary Completion
December 1, 2025
Study Completion
December 1, 2025
Last Updated
December 7, 2023
Record last verified: 2023-12
Data Sharing
- IPD Sharing
- Will not share